Nitrase Therapeutics is developing therapeutics targeting newly identified nitration enzymes, which are implicated in various diseases. Utilizing their proprietary NITROME Platform, the company identifies novel nitrases and their nitro-substrates to advance drug development and improve treatment outcomes.
Funding
Funding not disclosed
Founders
Product
Problem
Many diseases are influenced by nitration enzymes, but traditional therapeutic approaches have not directly targeted these enzymes due to a lack of understanding and tools for their identification and characterization. This gap hinders the development of effective treatments for a range of conditions where nitration plays a significant role.
Solution
Nitrase Therapeutics is developing a new class of therapeutics that target nitration enzymes, which have been implicated in a variety of diseases. The company's approach centers around its proprietary NITROME Platform, which is designed to identify novel nitrases and their nitro-substrates. By elucidating the biology of nitrases, Nitrase Therapeutics aims to unlock the therapeutic potential of these enzymes and develop novel treatments for a wide range of diseases.
Target Audience
The primary target audience includes patients suffering from diseases influenced by nitration enzymes, as well as pharmaceutical companies seeking novel drug targets and therapeutic approaches.
Features
- NITROME Platform for identifying novel nitrases and their nitro-substrates
- Focus on understanding the role of nitrases in various diseases
- Development of therapeutics that directly target nitration enzymes